Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer

International Journal of Cancer

Volumn 129, Issue 4, 2011, Pages 887-895

  Chu, Dake ^a   Zhang, Zixi ^a   Li, Yunming ^b   Zheng, Jianyong ^a   Dong, Guanglong ^a   Wang, Weizhong ^a   Ji, Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

gastric cancer; invasion; matrix metalloproteinase 9; metastasis; prognosis; relapse

Indexed keywords

GELATINASE B;

ADULT; AGE; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79959745908     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25734     Document Type: Article

References (43)

1. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S,. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-6.
2. Parsons SL, Watson SA, Brown PD, Collins HM, Steele RJ,. Matrix metalloproteinases. Br J Surg 1997; 84: 160-6. (Pubitemid 27073454)
3. Curran S, Murray GI,. Matrix metalloprteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000; 36: 1621-30. (Pubitemid 30616366)
4. Nagase H, Woessner JF, Jr,. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
5. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM,. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-49. (Pubitemid 30123793)
6. Park HI, Ni J, Gerkema FE, Liu D, Belozerov VE, Sang QX,. Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem 2000; 275: 20540-4. (Pubitemid 30457636)
7. Stetler-Stevenson WG,. The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am 2001; 10: 383-92.
8. Hidalgo M, Eckhardt SG,. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178-93. (Pubitemid 32166488)
9. Curran S, Murray GI,. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 300-8. (Pubitemid 29489213)
10. Stetler-Stevenson WG,. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990; 9: 289-303.
11. Chambers AF, Matrisian LM,. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-70. (Pubitemid 27371946)
12. Liotta LA, Stetler-Stevenson WG,. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990; 1: 99-106.
13. Roy R, Yang J, Moses MA,. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27: 5287-97.
14. Jeffery N, McLean MH, El-Omar EM, Murray GI,. The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. Histopathology 2009; 54: 820-8.
15. McDonnell S, Navre M, Coffey RJ, Jr, Matrisian LM,. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 1991; 4: 527-33.
16. Pyke C, Ralfkiaer E, Tryggvason K, Danø K,. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 1993; 142: 359-65. (Pubitemid 23057447)
17. Yoshimoto M, Itoh F, Yamamoto H, Hinoda Y, Imai K, Yachi A,. Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancers. Int J Cancer 1993; 54: 614-8. (Pubitemid 23188192)
18. Zeng ZS, Guillem JG,. Colocalisation of matrix metalloproteinase-9 mRNA and protein in human colorectal cancer stromal cells. Br J Cancer 1996; 74: 1161-7. (Pubitemid 26360102)
19. Zeng ZS, Huang Y, Cohen AM, Guillem JG,. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996; 14: 3133-40. (Pubitemid 26408807)
20. Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcroft JM, Rogers L, Stamp GW,. Stromal expression of 72kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992; 141: 389-96.
21. Leeman MF, McKay JA, Murray GI,. Matrix metalloproteinase-13 is associated with poor prognosis in colorectal cancer. J Clin Pathol 2002; 55: 758-62. (Pubitemid 35231907)
22. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kössi J, Hirsimäki P, Rahkonen O, Laato M,. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007; 121: 714-23. (Pubitemid 47106199)
23. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI,. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004; 10: 8229-34. (Pubitemid 40053382)
24. Lyall MS, Dundas SR, Curran S, Murray GI,. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 2006; 12: 1184-91. (Pubitemid 43342507)
25. Tang Y, Zhu J, Chen L, Chen L, Zhang S, Lin J,. Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer. Clin Cancer Res 2008; 14: 2870-7.
26. Zhao ZS, Wang YY, Ye ZY, Tao HQ,. Prognostic value of tumor-related molecular expression in gastric carcinoma. Pathol Oncol Res 2009; 15: 589-96.
27. Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE,. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998; 43: 791-7. (Pubitemid 28539658)
28. Mrena J, Wiksten JP, Nordling S, Kokkola A, Ristimäki A, Haglund C,. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol 2006; 59: 618-23. (Pubitemid 43886046)
29. Zhao ZS, Wang YY, Ye ZY, Tao HQ,. Prognostic value of tumor-related molecular expression in gastric carcinoma. Pathol Oncol Res 2009; 15: 589-96.
30. Nomura Y, Takasaki K, Tada M, Yoshimoto M, Ishida H, Murata N, Kubota S,. Pro-MMP-9 is associated with poor prognosis in gastric cancer. Scand J Gastroenterol 2007; 42: 1070-2. (Pubitemid 47301145)
31. de Mingo M, Morán A, Sánchez-Pernaute A, Iniesta P, Díez-Valladares L, Pérez-Aguirre E, de Juan C, García-Aranda C, Díaz-Lõpez A, García-Botella A, Martín-Antona E, Benito M, et al. Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma. Hepatogastroenterology 2007; 54: 315-9. (Pubitemid 46511697)
32. Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH, Lin JT,. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 2007; 13: 2054-60.
33. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP,. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7. (Pubitemid 28331029)
34. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD,. Reliability of immunohistochemical demonstration of oestrogen recep tors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000; 53: 125-30. (Pubitemid 30075056)
35. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
36. Peek RM, Jr, Blaser MJ,. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002; 2: 28-37. (Pubitemid 37328805)
37. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81.
38. Yang L,. Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006; 12: 17-20. (Pubitemid 43126077)
39. Peng ZR, Zhong WH, Liu J, Xiao PT,. Effects of the combination of hyperbaric oxygen and 5-fluorouracil on proliferation and metastasis of human nasopharyngeal carcinoma CNE-2Z cells. Undersea Hyperb Med 2010; 37: 141-50.
40. Coskun U, Yamac D, Gulbahar O, Sancak B, Karaman N, Ozkan S,. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response? Neoplasma 2007; 54: 348-52.
41. Wang W, McLeod HL, Cassidy J,. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 2003; 104: 504-11. (Pubitemid 36323923)
42. Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, Harada K, Kawaguchi S, Sato M,. Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer 2004; 108: 912-21. (Pubitemid 38112622)
43. Kyllönen H, Pasanen AK, Kuittinen O, Haapasaari KM, Turpeenniemi-Hujanen T,. Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody. Leuk Lymphoma 2009; 50: 1301-7.